GAITHERSBURG, Md.--(BUSINESS WIRE)--Smithers Avanza, a contract research organization (CRO) supporting the pharmaceutical and chemical industries, announced that Senior Toxicologist Caitlin Murphy, PhD has authored a white paper describing the company’s validation of its extended one-generation reproductive toxicity study (EOGRTS) capabilities. The white paper, available for download here, details the logistical pilot and provides insight on Smithers Avanza’s approach to these complex studies.
“It is our mission to provide clients with confidence in knowing that our team has the experience and capability to perform every study from the simplest to the most complex, all the while adhering strictly to OECD Good Laboratory Practice Principles,” said Michael Dorato, PhD, DABT, Fellow ATS, Executive Vice President, Smithers Avanza Toxicology Services. “The new white paper provides a glimpse into how our team operates and presents the team’s capability for EOGRTS programs.”
The EOGRTS represents the most recent and comprehensive guideline for determining the potential reproductive and developmental toxicity of industrial and agricultural chemicals. The design of the EOGRTS aims to reduce animal numbers which fits well with Smithers Avanza’s commitment to animal welfare.
Dr. Murphy will be present at the 2017 Society of Toxicology Annual Meeting to discuss EOGRTS and other Smithers Avanza services. This year’s event is being held at the Baltimore Convention Center in Baltimore, Maryland. Smithers Avanza is exhibiting at the conference and can be found at booth #2013.
For more information about the Smithers Avanza portfolio of services, visit http://smithersavanza.com.
About Smithers Avanza
Smithers Avanza is a contract research organization (CRO) supporting the pharmaceutical, agrochemical and chemical industries. Our scientists have expertise in large molecule bioanalysis, assay development, validation and sample analysis at our GLP- and GCP-compliant and CLIA-certified registered laboratory. Key expertise includes single dose to two-year general toxicology studies, vaccine safety testing, toxicokinetics, extended one-generation toxicity studies and infusion studies.